Xpert ® MTB/RIF for point-of-care diagnosis of TB in high-HIV burden, resource-limited countries: Hype or hope?

Expert Review of Molecular Diagnostics

Volumn 10, Issue 7, 2010, Pages 937-946

  Rie, Annelies Van ^a,b   Page Shipp, Liesl ^b   Scott, Lesley ^c   Sanne, Ian ^c   Stevens, Wendy ^c  

^a IL   (United States)

^b RIGHT TO CARE   (South Africa)

^c UNIVERSITY OF THE WITWATERSRAND   (South Africa)

Author keywords

diagnostics; GeneXpert ; HIV; NAAT; nucleic acid amplification test; resource limited countries; tuberculosis; Xpert MTB RIF

Indexed keywords

ISONIAZID; ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; ANTIVIRAL THERAPY; BIOSAFETY; DIAGNOSTIC ACCURACY; GENE AMPLIFICATION; HEALTH CARE COST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; POINT OF CARE TESTING; REVIEW; TUBERCULOSIS; DEVELOPING COUNTRY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOSPITAL INFORMATION SYSTEM; HUMAN IMMUNODEFICIENCY VIRUS; ISOLATION AND PURIFICATION; MICROBIOLOGY; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; PATHOGENICITY;

ANTI-BACTERIAL AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DEVELOPING COUNTRIES; HIV; HIV INFECTIONS; HUMANS; MYCOBACTERIUM TUBERCULOSIS; POINT-OF-CARE SYSTEMS; TUBERCULOSIS; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 79951654084     PISSN: 14737159     EISSN: 17448352     Source Type: Journal    
DOI: 10.1586/erm.10.67     Document Type: Review

References (36)

1. WHO. Global Tuberculosis Control: Surveillance, Planning, Financing: WHO Report 2009. WHO, Geneva, Switzerland (2009).
2. WHO. Global Tuberculosis Control. A Short Update to the 2009 Report. WHO, Geneva, Switzerland (2009).
3. Mathew P, Kuo YH, Vazirani B, Eng RH, Weinstein MP. Are three sputum acid-fast bacillus smears necessary for discontinuing tuberculosis isolation? J. Clin. Microbiol. 40, 3482-3484 (2002). (Pubitemid 34977473)
4. Mugusi F, Villamor E, Urassa W, Saathoff E, Bosch RJ, Fawzi WW. HIV co-infection, CD4 cell counts and clinical correlates of bacillary density in pulmonary tuberculosis. Int. J. Tuberc. Lung Dis. 10, 663-669 (2006). (Pubitemid 43845028)
5. van Kampen SC, Anthony RM, Klatser PR. The realistic performance achievable with mycobacterial automated culture systems in high and low prevalence settings. BMC Infect. Dis. 10, 93 (2010).
6. Pai M, Minion J, Sohn H, Zwerling A, Perkins MD. Novel and improved technologies for tuberculosis diagnosis: progress and challenges. Clin. Chest Med. 30, 701-716, viii (2009).
7. WHO. Strategic and Technical Advisory for Tuberculosis. Report of the Ninth Meeting. 9-11 November 2009. WHO, Geneva, Switzerland (2009).
8. Davies PD, Pai M. The diagnosis and misdiagnosis of tuberculosis. Int. J. Tuberc. Lung Dis. 12, 1226-1234 (2008).
9. Centers for Disease Control and Prevention (CDC). Updated guidelines for the use of nucleic acid amplification tests in the diagnosis of tuberculosis. MMWR Morb. Mortal. Wkly Rep. 58, 7-10 (2009).
10. Ling DI, Flores LL, Riley LW, Pai M. Commercial nucleic-acid amplification tests for diagnosis of pulmonary tuberculosis in respiratory specimens: meta-analysis and meta-regression. PLoS ONE 3, e1536 (2008).
11. Paramasivan CN, Lee E, Kao K et al. Experience establishing tuberculosis laboratory capacity in a developing country setting. Int. J. Tuberc. Lung Dis. 14, 59-64 (2010).
12. Boehme CC, Nabeta P, Henostroza G et al. Operational feasibility of using loopmediated isothermal amplification for diagnosis of pulmonary tuberculosis in microscopy centers of developing countries. J. Clin. Microbiol. 45, 1936-1940 (2007). (Pubitemid 46933929)
13. Helb D, Jones M, Story E et al. Rapid detection of Mycobacterium tuberculosis and rifampin-resistance using on-demand, near patient technology. J. Clin. Microbiol. 48(1), 229-237 (2010).
14. Blakemore R, Story E, Helb D et al. Evaluation of the analytical performance of the Xpert MTB/RIF assay. J. Clin. Microbiol. 48, 2495-2501 (2010).
15. Banada PP, Sivasubramani SK, Blakemore R et al. Containment of bioaerosol infection risk by the Xpert(R) MTB/RIF assay and its applicability to point-of-care settings. J. Clin. Microbiol. DOI: JCM.01053-10v1 (2010) (Epub ahead of print).
16. Xpert® MTB/RIF, package insert. Cepheid, CA, USA (2009).
17. Lebrun L, Mathieu D, Saulnier C, Nordmann P. Limits of commercial molecular tests for diagnosis of pulmonary tuberculosis. Eur. Respir. J. 10, 1874-1876 (1997). (Pubitemid 27368385)
18. Boehme CC, Nabeta P, Hillemann D et al. Rapid molecular detection of tuberculosis and rifampin resistance. N. Engl. J. Med. 363(11), 1005-1015 (2010).
19. Barnard M, Albert H, Coetzee G, O'Brien R, Bosman ME. Rapid molecular screening for multidrug-resistant tuberculosis in a high-volume public health laboratory in South Africa. Am. J. Respir. Crit. Care Med. 177, 787-792 (2008). (Pubitemid 351490566)
20. WHO. Molecular Line Probe Assays for Rapid Screening of Patients at Risk of Multidrug-Resistant Tuberculosis (MDRTB). WHO, Geneva, Switzerland (2008).
21. Matthys F, Rigouts L, Sizaire V et al. Outcomes after chemotherapy with WHO category II regimen in a population with high prevalence of drug-resistant tuberculosis. PLoS ONE 4, e7954 (2009).
22. Drobniewski FA, Wilson SM. The rapid diagnosis of isoniazid and rifampicin resistance in Mycobacterium tuberculosis-a molecular story. J. Med. Microbiol. 47, 189-196 (1998). (Pubitemid 28090047)
23. Traore H, Fissette K, Bastian I, Devleeschouwer M, Portaels F. Detection of rifampicin resistance in Mycobacterium tuberculosis isolates from diverse countries by a commercial line probe assay as an initial indicator of multidrug resistance. Int. J. Tuberc. Lung Dis. 4, 481-484 (2000). (Pubitemid 30256852)
24. Getahun H, Harrington M, O'Brien R, Nunn P. Diagnosis of smear-negative pulmonary tuberculosis in people with HIV infection or AIDS in resourceconstrained settings: informing urgent policy changes. Lancet 369, 2042-2049 (2007). (Pubitemid 46908825)
25. Monkongdee P, McCarthy KD, Cain KP et al. Yield of acid-fast smear and mycobacterial culture for tuberculosis diagnosis in people with human immunodeficiency virus. Am. J. Respir. Crit. Care Med. 180, 903-908 (2009).
26. Aabye MG, Ravn P, PrayGod G et al. The impact of HIV infection and CD4 cell count on the performance of an interferon g release assay in patients with pulmonary tuberculosis. PLoS ONE 4, e4220 (2009).
27. Raby E, Moyo M, Devendra A et al. The effects of HIV on the sensitivity of a whole blood IFN-g release assay in Zambian adults with active tuberculosis. PLoS ONE 3, e2489 (2008).
28. Elzi L, Schlegel M, Weber R et al. Reducing tuberculosis incidence by tuberculin skin testing, preventive treatment, and antiretroviral therapy in an area of low tuberculosis transmission. Clin. Infect. Dis. 44, 94-102 (2007). (Pubitemid 44968992)
29. Ait-Khaled N, Alarcon E, Bissell K et al. Isoniazid preventive therapy for people living with HIV: public health challenges and implementation issues. Int. J. Tuberc. Lung Dis. 13, 927-935 (2009).
30. Mtei L, Matee M, Herfort O et al. High rates of clinical and subclinical tuberculosis among HIV-infected ambulatory subjects in Tanzania. Clin. Infect. Dis. 40, 1500-1507 (2005). (Pubitemid 40628639)
31. Corbett EL, Bandason T, Cheung YB et al. Epidemiology of tuberculosis in a high HIV prevalence population provided with enhanced diagnosis of symptomatic disease. PLoS Med. 4, e22 (2007).
32. Lawn SD, Wilkinson RJ, Lipman MC, Wood R. Immune reconstitution and 'unmasking' of tuberculosis during antiretroviral therapy. Am. J. Respir. Crit. Care Med. 177, 680-685 (2008). (Pubitemid 351490554)
33. Lawn SD, Edwards DJ, Wood R. Reducing the burden of tuberculosis presenting during the initial months of antiretroviral therapy in resource-limited settings. Clin. Infect. Dis. 50, 124-125 (2010).
34. Lawn SD, Edwards DJ, Kranzer K, Vogt M, Bekker LG, Wood R. Urine lipoarabinomannan assay for tuberculosis screening before antiretroviral therapy diagnostic yield and association with immune reconstitution disease. AIDS 23, 1875-1880 (2009).
35. Lawn SD, Harries AD, Anglaret X, Myer L, Wood R. Early mortality among adults accessing antiretroviral treatment programmes in sub-Saharan Africa. AIDS 22, 1897-1908 (2008).
36. Van Deun A, Martin A, Palomino JC. Diagnosis of drug-resistant tuberculosis: reliability and rapidity of detection. Int. J. Tuberc. Lung Dis. 14, 131-140 (2010).